NCT06353321View on ClinicalTrials.gov

Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1

RecruitingOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 12, 2025

Study Completion Date

December 14, 2025

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

PET-CT imaging subsystem of the RefleXion X1 System Device

Imaging performed only on the X1 platform immediately following already planned imaging using Illuccix for standard of care indications in men with prostate cancer of various stages, in order to assess performance of the X1 in comparison to diagnostic imaging scanners

Trial Locations (1)

75390

RECRUITING

Ut Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

RefleXion Medical
All Listed Sponsors
collaborator

RefleXion Medical

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER